July 02, 2025

FDA Approves Ready-to-Infuse Vancomycin

Tyzavan is the first FDA-approved vancomycin formulation available at room temperature that requires no compounding, thawing, or dilution, enabling faster treatment in time-critical infections like sepsis.

Conexiant

June 24, 2025

Do CBC Ratios Predict RA Mortality?

Elevated SIRI, NLR, and MLR from routine blood counts independently predicted higher all-cause mortality among patients with rheumatoid arthritis.

Conexiant

June 20, 2025

Platelet Indices Signal Aspirin Resistance in Preeclampsia

New research links changes in platelet count and volume to aspirin nonresponsiveness in pregnant women who develop preeclampsia, offering insights into potential biomarkers for risk monitoring.

Conexiant

June 17, 2025

Cellular Essence of Pathology

Our image of the month highlights the beauty in cellular analysis

The Pathologist

June 11, 2025

8-Week Oral Therapy Approved for Acute HCV

The FDA has approved Mavyret for the treatment of acute hepatitis C, offering physicians a pangenotypic, 8-week oral regimen for early intervention.

Conexiant

June 09, 2025

Dark Metabolome Debate: A Call for Context

Shuzhao Li sees no fundamental disagreement between “camps”

The Analytical Scientist

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

February 12, 2025

FDA & EMA: Submitted Trial Data Discrepancies

Sample size discrepancies were identified in 13 trials (65%), with 8 differing by more than 10%.

Conexiant

March 21, 2025

Vutrisiran Receives FDA Nod for ATTR Amyloidosis With Cardiomyopathy

The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Conexiant